Emerson Firm PLLC Announces Ongoing Investigation Involving Toyota 4Runner, Avalon, Camry, Corolla, Highlander, Land Cruiser, Sequoia, Sienna, Tacoma, Tundra, & Lexus Vehicles
February 12, 2020 21:00 ET
|
Emerson Scott LLP
HOUSTON, Feb. 12, 2020 (GLOBE NEWSWIRE) -- Emerson Firm, PLLC announces a continuing investigation of a hugely significant issue involving the fuel pump defect of certain Toyota vehicles. This...
Sienna Biopharmaceuticals Announces Court Approval of Chapter 11 Bidding Procedures
November 14, 2019 16:05 ET
|
Sienna Biopharmaceuticals, Inc.
WESTLAKE VILLAGE, Calif., Nov. 14, 2019 (GLOBE NEWSWIRE) -- Sienna Biopharmaceuticals, Inc. (Nasdaq:SNNA) (the “Company”), a clinical-stage biopharmaceutical company, today announced that, on...
Sienna Biopharmaceuticals Announces Successful Appeal of Nasdaq Delisting Notice
November 14, 2019 08:30 ET
|
Sienna Biopharmaceuticals, Inc.
-- Sienna’s common stock to remain conditionally listed during the Chapter 11 asset sale process WESTLAKE VILLAGE, Calif., Nov. 14, 2019 (GLOBE NEWSWIRE) -- Sienna Biopharmaceuticals, Inc....
Sienna Biopharmaceuticals Files 510(k) Submission with FDA for SNA-001, its Novel Silver Photoparticle Technology to Remove Light Hair
October 07, 2019 08:30 ET
|
Sienna Biopharmaceuticals, Inc.
WESTLAKE VILLAGE, Calif., Oct. 07, 2019 (GLOBE NEWSWIRE) -- Sienna Biopharmaceuticals, Inc. (Nasdaq:SNNA), a clinical-stage biopharmaceutical company, today announced that the Company has filed a...
Sienna Biopharmaceuticals Initiates Voluntary Chapter 11 Protection Proceeding
September 17, 2019 08:30 ET
|
Sienna Biopharmaceuticals, Inc.
WESTLAKE VILLAGE, Calif., Sept. 17, 2019 (GLOBE NEWSWIRE) -- Sienna Biopharmaceuticals, Inc. (Nasdaq:SNNA), a clinical-stage biopharmaceutical company, today announced that it has elected to file a...
Sienna Biopharmaceuticals Engages Cowen to Explore Financial and Strategic Alternatives
August 05, 2019 09:05 ET
|
Sienna Biopharmaceuticals, Inc.
WESTLAKE VILLAGE, Calif., Aug. 05, 2019 (GLOBE NEWSWIRE) -- Sienna Biopharmaceuticals, Inc. (Nasdaq:SNNA), a clinical-stage biopharmaceutical company, today announced that the Company has retained...
Sienna Biopharmaceuticals to Present at BMO Capital Markets Healthcare Conference
June 20, 2019 09:05 ET
|
Sienna Biopharmaceuticals, Inc.
WESTLAKE VILLAGE, Calif., June 20, 2019 (GLOBE NEWSWIRE) -- Sienna Biopharmaceuticals, Inc. (Nasdaq:SNNA), a clinical-stage biopharmaceutical company, today announced that Frederick C. Beddingfield...
Sienna Biopharmaceuticals Announces Late-Breaking Oral Presentation of Phase 2b Trial Results of its Topical, Non-Steroidal TrkA Inhibitor SNA-120 (0.05%) at 24th World Congress of Dermatology
June 10, 2019 09:05 ET
|
Sienna Biopharmaceuticals, Inc.
-- Phase 2b Trial Results Demonstrated SNA-120 Had Significant Impact on Psoriasis and Was Well-Tolerated WESTLAKE VILLAGE, Calif., June 10, 2019 (GLOBE NEWSWIRE) -- Sienna Biopharmaceuticals, Inc....
Sienna Biopharmaceuticals to Present at Dermatology Drug Development Summit Europe
May 21, 2019 09:05 ET
|
Sienna Biopharmaceuticals, Inc.
WESTLAKE VILLAGE, Calif., May 21, 2019 (GLOBE NEWSWIRE) -- Sienna Biopharmaceuticals, Inc. (Nasdaq:SNNA), a clinical-stage biopharmaceutical company, today announced that Paul F. Lizzul, M.D.,...
Sienna Biopharmaceuticals Announces SNA-120 (0.05%) Biopsy Data Demonstrate Positive Impact on Key Inflammatory Cytokines, including IL-23 and IL-17, in Psoriasis
May 14, 2019 09:05 ET
|
Sienna Biopharmaceuticals, Inc.
-- Biopsy data support strong clinical effect observed in Phase 2 trials with SNA-120 -- Following Positive End-of-Phase 2 meeting with FDA, Sienna continues toward enrolling first patient in Phase...